|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/24 | |
| A61P 25/00 | |||
| A61P 25/28 |
| (11) | Number of the document | 2411036 |
| (13) | Kind of document | T |
| (96) | European patent application number | 10756916.2 |
| Date of filing the European patent application | 2010-03-26 | |
| (97) | Date of publication of the European application | 2012-02-01 |
| (45) | Date of publication and mention of the grant of the patent | 2017-03-15 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2010/028839 |
| Date | 2010-03-26 |
| (87) | Number | WO 2010/111598 |
| Date | 2010-09-30 |
| (30) | Number | Date | Country code |
| 163556 P | 2009-03-26 | US |
| (72) |
CHOPP, Michael, US
ZHANG, Zhenggang, US
MORRIS, Daniel C., US
|
| (73) |
Henry Ford Health System,
1 Ford Place, Detroit, MI 48202,
US
|
| (54) | THYMOSIN BETA4 FOR USE IN TREATING A NEURAL INJURY |
| THYMOSIN BETA4 FOR USE IN TREATING A NEURAL INJURY |